Clinical Trial Update: Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluated abatacept (BMS-188667) added to background non-biologic DMARDs in active rheumatoid arthritis patients who had an inadequate …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Abatacept (abatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2011-06-02